Literature DB >> 19443580

Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues.

Bea Waser1, Maria-Luisa Tamma, Renzo Cescato, Helmut R Maecke, Jean Claude Reubi.   

Abstract

UNLABELLED: The successful peptide receptor imaging of tumors, as exemplified for somatostatin receptors, is based on the overexpression of peptide receptors in selected tumors and the high-affinity binding to these tumors of agonist radioligands that are subsequently internalized into the tumor cells in which they accumulate. Although in vitro studies have shown ample evidence that the ligand-receptor complex is internalized, in vivo evidence of agonist-induced internalization of peptide receptors, such as somatostatin receptors, is missing.
METHODS: Rats subcutaneously transplanted with the somatostatin receptor subtype 2 (sst(2))-expressing AR42J tumor cells were treated with intravenous injections of various doses of the sst(2) agonist [Tyr(3), Thr(8)]-octreotide (TATE) or of the sst(2) antagonist 1,4,7,10-tetraazacyclododecane-N,N',N'',N''',-tetraacetic acid (DOTA)-Bass and were sacrificed at various times ranging from 2.5 min to 24 h after injection. The tumors and pancreas were then removed from each animal. All tissue samples were processed for sst(2) immunohistochemistry using sst(2)-specific antibodies.
RESULTS: Compared with the sst(2) receptors in untreated animals, which localized at the plasma membrane in pancreatic and AR42J tumor cells, the sst(2) receptors in treated animals are detected intracellularly after an intravenous injection of the agonist TATE. Internalization is fast, as the receptors are already internalizing 2.5 min after TATE injection. The process is extremely efficient, as most of the cell surface receptors internalize into the cell and are found in endosomelike structures after TATE injection. The internalization is most likely reversible, because 24 h after injection the receptors are again found at the cell surface. The process is also agonist-dependent, because internalization is seen with high-affinity sst(2) agonists but not with high-affinity sst(2) antagonists. The same internalization properties are seen in pancreatic and AR42J tumor cells. They can further be confirmed in vitro in human embryonic kidney-sst(2) cells, with an immunofluorescence microscopy-based sst(2) internalization assay.
CONCLUSION: These animal data strongly indicate that the process of in vivo sst(2) internalization after agonist stimulation is fast, extremely efficient, and fully functional under in vivo conditions in neoplastic and physiologic sst(2) target tissues. This molecular process is, therefore, likely to be responsible for the high and long-lasting uptake of sst(2) radioligands seen in vivo in sst(2)-expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443580     DOI: 10.2967/jnumed.108.061457

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  35 in total

1.  Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.

Authors:  Beatrice Waser; Renzo Cescato; Qisheng Liu; Yachu J Kao; Meike Körner; Emanuel Christ; Agnes Schonbrunn; Jean Claude Reubi
Journal:  Am J Pathol       Date:  2012-05       Impact factor: 4.307

Review 2.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE.

Authors:  Qing Xie; Teli Liu; Jing Ding; Nina Zhou; Xiangxi Meng; Hua Zhu; Nan Li; Jiangyuan Yu; Zhi Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-25       Impact factor: 9.236

4.  Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy.

Authors:  Constantin Lapa; Rudolf A Werner; Christina Bluemel; Katharina Lückerath; Andreas Schirbel; Alexander Strate; Andreas K Buck; Ken Herrmann
Journal:  EJNMMI Res       Date:  2014-08-23       Impact factor: 3.138

Review 5.  Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine.

Authors:  Kegan S Sunderland; Mingying Yang; Chuanbin Mao
Journal:  Angew Chem Int Ed Engl       Date:  2017-01-24       Impact factor: 15.336

6.  The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever....

Authors:  Lisa Bodei; Mark Kidd; Vikas Prasad; Richard P Baum; Ignat Drozdov; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12       Impact factor: 9.236

7.  Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues.

Authors:  Jean Claude Reubi
Journal:  Endocrine       Date:  2014-06-10       Impact factor: 3.633

8.  Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Authors:  Phillip G Claringbold; Paul A Brayshaw; Richard A Price; J Harvey Turner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10-30       Impact factor: 9.236

9.  Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.

Authors:  Jean Claude Reubi; Judit Erchegyi; Renzo Cescato; Beatrice Waser; Jean E Rivier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-16       Impact factor: 9.236

10.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.